Literature DB >> 11834594

BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

Christine Stadelmann1, Martin Kerschensteiner, Thomas Misgeld, Wolfgang Brück, Reinhard Hohlfeld, Hans Lassmann.   

Abstract

Recent immunohistological and imaging studies emphasize the crucial role of axonal injury in determining the extent of permanent neurological deficits in patients with multiple sclerosis. We have recently shown that human immune cells are capable of producing the neurotrophin brain-derived neurotrophic factor (BDNF), which can prevent axonal and neuronal damage after various pathological insults. BDNF imported into the CNS by immune cells would thus be an attractive candidate for mediating neuroprotective effects in multiple sclerosis. The aim of the present study was to perform a detailed immunohistochemical analysis of the expression of BDNF and its receptor truncated trkB tyrosine kinase receptor (gp145trkB) in a series of multiple sclerosis brain lesions. Our data show that various types of neurones throughout the brain are BDNF immunopositive in multiple sclerosis patients as well as in controls. Furthermore, in multiple sclerosis lesions, BDNF is primarily present in immune cells (T cells, macrophages/microglia) and reactive astrocytes. The number of BDNF immunopositive cells correlates with lesional demyelinating activity. The BDNF receptor gp145trkB is found in neurones in the immediate vicinity of multiple sclerosis plaques as well as in reactive astrocytes within the lesion, but not in immune cells. Our results demonstrate that both BDNF and gp145trkB are expressed in multiple sclerosis lesions. This suggests that BDNF and gp145trkB are involved in immune-mediated neuroprotective interactions in multiple sclerosis, and supports the concept that immune cells produce both damaging and protective factors in multiple sclerosis lesions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834594     DOI: 10.1093/brain/awf015

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  99 in total

Review 1.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

Review 2.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 3.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

Review 4.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 5.  No quiet surrender: molecular guardians in multiple sclerosis brain.

Authors:  Lawrence Steinman
Journal:  J Clin Invest       Date:  2015-04-01       Impact factor: 14.808

6.  Expression of stathmin, a developmentally controlled cytoskeleton-regulating molecule, in demyelinating disorders.

Authors:  Aixiao Liu; Christine Stadelmann; Mario Moscarello; Wolfgang Bruck; Andre' Sobel; Fabrizio G Mastronardi; Patrizia Casaccia-Bonnefil
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

Review 7.  Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.

Authors:  Tjalf Ziemssen
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

8.  How promising is hematopoetic stem cell transplantation in multiple sclerosis?

Authors:  Reinhard Hohlfeld
Journal:  J Neurol       Date:  2002-09       Impact factor: 4.849

Review 9.  [Multiple sclerosis: potential therapeutic options and update of ongoing studies].

Authors:  H Wiendl; H C Lehmann; R Hohlfeld; H-P Hartung; B C Kieseier
Journal:  Nervenarzt       Date:  2004-06       Impact factor: 1.214

10.  IFN-β alters neurotrophic factor expression in T cells isolated from multiple sclerosis patients - implication of novel neurotensin/NTSR1 pathway in neuroprotection.

Authors:  John Soltys; Julia Knight; Eugene Scharf; David Pitt; Yang Mao-Draayer
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.